Sexual orientation and anabolic-androgenic steroids in U.S. adolescent boys.
OBJECTIVE
We compared the lifetime prevalence of anabolic-androgenic steroid (AAS) misuse among sexual minority versus heterosexual U.S. adolescent boys, and secondarily, sought to explore possible intermediate variables that may explain prevalence differences.


METHODS
Participants were 17,250 adolescent boys taken from a pooled data set of the 14 jurisdictions from the 2005 and 2007 Youth Risk Behavior Surveys that assessed sexual orientation. Data were analyzed for overall prevalence of AAS misuse and possible intermediary risk factors.


RESULTS
Sexual minority adolescent boys were at an increased odds of 5.8 (95% confidence interval 4.1-8.2) to report a lifetime prevalence of AAS (21% vs. 4%) compared with their heterosexual counterparts, P < .001. Exploratory analyses suggested that increased depressive symptoms/suicidality, victimization, and substance use contributed to this disparity.


CONCLUSIONS
This is the first known study to test and find substantial health disparities in the prevalence of AAS misuse as a function of sexual orientation. Prevention and intervention efforts are needed for sexual minority adolescent boys.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, The Fenway Institute, Boston, Massachusetts.
Aaron J
AJ
Blashill
Steven A
SA
Safren
D000293:Adolescent; D045930:Anabolic Agents / Q000008:administration & dosage; D000728:Androgens / Q000008:administration & dosage; D006801:Humans; D008297:Male; D012309:Risk-Taking; D012725:Sexual Behavior / Q000523:psychology*; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology*; D014481:United States / Q000453:epidemiology
D045930:Anabolic Agents; D000728:Androgens
adolescents; anabolic-androgenic steroids; boys; sexual orientation